Chemistry:Upamostat
From HandWiki
Short description: Chemical compound
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C32H47N5O6S |
| Molar mass | 629.82 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Upamostat (WX-671, Mesupron) is a drug which acts as an inhibitor of the serine protease enzyme urokinase. It is under development as a potential treatment agent for pancreatic cancer, acting to inhibit tumour metastasis.[1][2][3]
References
- ↑ "Benzamide and Benzamidine Compounds as New Inhibitors of Urokinasetype Plasminogen Activators". Mini Reviews in Medicinal Chemistry 18 (20): 1753–1758. 2018. doi:10.2174/1389557518666180816110740. PMID 30112993.
- ↑ "Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer". British Journal of Cancer 108 (4): 766–70. March 2013. doi:10.1038/bjc.2013.62. PMID 23412098.
- ↑ "Activation of the anti-cancer agent upamostat by the mARC enzyme system". Xenobiotica; the Fate of Foreign Compounds in Biological Systems 43 (9): 780–4. September 2013. doi:10.3109/00498254.2013.767481. PMID 23379481.
